Comparative Pharmacology
Head-to-head clinical analysis: SONATA versus VALMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SONATA versus VALMID.
SONATA vs VALMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Zaleplon is a non-benzodiazepine hypnotic that selectively binds to the benzodiazepine type 1 (BZ1) receptor subtype on the gamma-aminobutyric acid (GABA) A receptor complex, potentiating GABA-mediated chloride ion influx and neuronal inhibition.
Valproate increases gamma-aminobutyric acid (GABA) concentrations in the brain either by inhibiting GABA transaminase or by increasing glutamic acid decarboxylase activity, thereby enhancing inhibitory neurotransmission.
10 mg orally at bedtime; range 5-20 mg; maximum 20 mg per day.
250 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1 hour (range 0.7–1.7 h) in healthy adults; elderly patients and those with hepatic impairment may have prolonged half-life (up to 2–3 h).
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 10-20 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Approximately 83% of administered radioactivity is excreted in urine (with less than 1% as unchanged drug) and 17% in feces.
Renal excretion accounts for >90% of elimination, primarily as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic